Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26375634 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL22018257 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL24530643 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL25467832 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL26375636 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL26375635 | 0.98 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL20224766 | 0.94 | GBA1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL26375648 | 0.90 | OPRL1 (0.39) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL25467830 | 0.86 | HRH3 (0.39) | GNAO1GNAI3GNAI1SIGMAR1GBA1 | |
| SCHEMBL10052289 | 0.86 | ARG1 (0.38) | GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | GNAO1 67/4885GNAI3 82/4885GNAI1 17/4885 |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | HAVCR2, AR, AKR7A2 | GNAO1 1154/4885GNAI3 1528/4885GNAI1 1342/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GNAO1 3206/4885GNAI3 3162/4885GNAI1 3170/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | GNAO1 1665/4885GNAI3 2167/4885GNAI1 1516/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | GNAO1 3206/4885GNAI3 3162/4885GNAI1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.